Rubicon Research Ltd
Rubicon Research Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Rubicon Research Ltd's next results in your feed
Guidance rank: #18 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Rubicon Research Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Q2 FY27 financials:.
From Rubicon Research Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Rubicon Research's revenue grow in the September 2026 quarter?
- Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10).
- USD revenue for Q2 FY27: $58 million, up over 5% sequentially from $55 million in Q1 FY27 (Page 11).
- Commercialization rate of approved products stands at 84% as of 30 Sep 2026 (Page 30).
- Explicit revenue outlook: Strong revenue visibility mentioned with sequential USD revenue growth expected to continue post Q2 FY27 (Page 11).
2 more points from Rubicon Research Ltd's call on revenue
Create a free account to keep reading this call
What happened to Rubicon Research's margins in Q2 FY27?
See what Rubicon Research Ltd said on profitability & margins — free account, 30 seconds.
What capex is Rubicon Research planning?
- FY2026: Acquisition of Alkem’s Pithampur manufacturing site (US FDA inspected; 125,000 m² plot, ~16,000 m² built-up area); status: acquired, commercialisation pending.
- FY2026: Acquisition of AimRx 3PL LLC (US-based logistics provider with warehouse in East Brunswick, NJ); status: operational.
- April 2026: Acquisition of Arinna Lifesciences Ltd. (India CNS formulations company with 60 brands and ~160 sales reps); status: financials consolidated Q1 FY27.
- July 2026: Acquisition of InvaTech’s New Jersey manufacturing site (US FDA inspected for oral solids and liquids, similar size to Satara site); adjacent to AimRx facility; status: acquired, commercialisation pending.
- Capex includes ₹658 million in H1 FY27 (part of total investing activities of ₹1,719 million).
2 more points from Rubicon Research Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Rubicon Research raising money or cutting debt?
See what Rubicon Research Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Rubicon Research's order book?
See what Rubicon Research Ltd said on order book & pipeline — free account, 30 seconds.
Rubicon Research Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Rubicon Research Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 576 |
| Operating profit (EBITDA) | 144 |
| Operating margin | 25% |
| Profit before tax | 117 |
| Net profit (PAT) | 90 |
| EPS (₹) | 5.47 |
Source: Rubicon Research Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹534 Cr, net profit ₹85 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Symbiotec Pharma (Q2 FY27)
280 Cr, up 43% YoY from Rs. Key investor presentation takeaways from Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation — and how it ranks against sector p
- Hester Bios (Q2 FY27)
Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). Key results statement takeaways from Hester Biosciences Ltd's Q
- Glenmark Pharmaceuticals (Q2 FY27)
42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against
- Windlas Biotech (Q2 FY27)
264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rubicon Research Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rubicon Research Ltd Q2 FY27 results?
Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Q2 FY27 financials:.
What is Rubicon Research Ltd share price analysis?
Rubicon Research Ltd currently shows a neutral. The stock trades at a P/E of 98.6 with a market cap of ₹28,411 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research Ltd planning capital expenditure?
FY2026: Acquisition of Alkem’s Pithampur manufacturing site (US FDA inspected; 125,000 m² plot, ~16,000 m² built-up area); status: acquired, commercialisation pending.
Keep Rubicon Research Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.